Navigation Links
Treatment of silent acid reflux does not improve asthma in children, NIH study finds
Date:1/24/2012

Adding the acid reflux drug lansoprazole to a standard inhaled steroid treatment for asthma does not improve asthma control in children who have no symptom of acid reflux, according to a new study funded in part by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health. Lansoprazole therapy slightly increased the risk of sore throats and other respiratory problems in children, however.

Results of this study, which was also sponsored by the American Lung Association (ALA), will appear Jan. 25 in the Journal of the American Medical Association.

"This important finding could help prevent giving unnecessary medication to children," said Susan B. Shurin, M.D., acting director of the NHLBI and a board-certified pediatrician. "Doctors have suspected that acid reflux that does not cause symptoms interferes with asthma control and should be treated. This study shows that acid reflux medication should not be given to children for possible silent reflux in hopes of improving asthma control."

Shurin added that a previous NHLBI/ALA-funded trial from 2009 found that acid reflux drugs do not improve asthma control in adults who do not have symptoms of acid reflux.

Acid reflux occurs when stomach acid escapes to the adjoining esophagus. This condition occurs commonly in children and adults with asthma, although sometimes it can be silent and show none of the obvious symptoms such as heartburn, vomiting, and difficulty swallowing. Lansoprazole suppresses the production of stomach acid.

To test whether reflux treatment improves asthma control in children, researchers at 18 ALA Asthma Clinical Research Centers across the United States studied 306 children and teenagers of various ethnicities aged 6-17 years. All study participants had inadequately controlled asthma despite taking inhaled corticosteroids. Approximately 40 percent of tested participants were identified as having acid reflux. Each participant was randomly assigned to receive a daily dose of lansoprazole or an inactive placebo pill along with their inhaled steroid therapy.

After 24 weeks of treatment, there were no significant differences in severity of asthma symptoms, overall lung function, or asthma-related quality of life between the lansoprazole and placebo treatment groups. These similar results were seen both in the whole study group as well as among the study subgroup that was positively identified as having acid reflux.

Children in the lansoprazole group did report more frequent adverse effects such as sore throat (52 percent versus 39 percent in placebo), upper respiratory infection (63 percent versus 49 percent) and/or bronchitis (7 percent versus 2 percent).

"This study addresses an important knowledge gap identified in the asthma guidelines," noted James P. Kiley, Ph.D., director of the NHLBI's Division of Lung Diseases. "This study, as well as the previous reflux trial in adults, will inform future guidelines for the treatment of asthma."

In the United States, asthma affects more than 7 million children and teenagers under age 18 years. Asthma disproportionately affects minorities and those with lower incomes. There is no cure for asthma, but guideline-based treatment can help prevent symptoms and attacks (shortness of breath, wheezing, and chest tightness) and enable children with asthma to lead active lives.

The lansoprazole and placebo used in the study was provided by its manufacturer, Takeda Pharmaceuticals, North America. In addition, GlaxoSmithKline provided Albuterol HFA, a bronchodilator that was used in the evaluation of study participants.


'/>"/>
Contact: NHLBI Communications
NHLBI_news@nhlbi.nih.gov
301-496-4236
NIH/National Heart, Lung and Blood Institute
Source:Eurekalert

Related medicine news :

1. Abnormal chromosome indicator of treatment and outcome in patients with rare brain tumor
2. Study tests new treatments for the winter blues
3. 2012 Gastroinstestinal Cancers Symposium reveals new advances aimed at improving treatment, prognosis and detection of GI cancers
4. Newborn screening program aims to help transform treatments for genetic diseases detected at birth
5. UH Case Medical Center publishes study on novel treatment for skin lymphoma
6. Combining 2 anti-HER2 drugs may provide better preoperative breast cancer treatment
7. Novel Stem Cell Treatment May Hold Promise for Type 1 Diabetes
8. Gene identified as a new target for treatment of aggressive childhood eye tumor
9. Treatment with light benefits Alzheimers patients, Wayne State University finds
10. Parkinsons treatment shows positive results in clinical testing
11. Short, sharp shock treatment for E. coli
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), ... company,s second affiliate in Latin America . ... ... Colombia ... ...
Breaking Medicine Technology: